EUCTR2006-002588-22-IT进行中（未招募）不适用
A phase II, multicenter study of etoposide, aracytin, dexamethasone and bortezomib in patients affected by relapsed/refractory multiple myeloma previously treated with thalidomide - ND
AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI0 个研究点开始时间: 2007年7月12日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1-MM relapsed/refractory after thalidomide treatment
- •2-age < 80 years
- •3-written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1-De novo MM
- •2-Pregnancy or lactating women
- •3-contracceptive methods refusal
- •4-inadequate hepatic, cardiac, renal and cerebral function
研究者
相似试验
进行中（未招募）
1 期
REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerExtended disease Small Cell Lung Cancer (ED-SCLC)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003090-42-ITEORTC AISBL/IVZW118
进行中（未招募）
1 期
REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerExtended disease Small Cell Lung Cancer (ED-SCLC)MedDRA version: 21.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003090-42-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)118
Unknown
2 期
Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast CancerBreast CancerNCT01492556Chinese Academy of Medical Sciences100
进行中（未招募）
2 期
Study of etoposide carboplatin chemotherapy in combination with pembrolizumab and lenvatinib therapy in advanced high-grade neuroendocrine tumoursCancerISRCTN12812346Imperial College London20
进行中（未招募）
不适用
A phase II study of etoposide, oxaliplatin and capecitabine in patients with advanced hepatocellular carcinomaAdvanced Hepatocellular carcinomaEUCTR2005-003187-32-DKDepartment of Oncology, Rigshospitalet39